Simon E. Richardson

Simon E. Richardson

Auto-generated profile, based on publicly available information

Simon E. Richardson

Department of Haematology, Cambridge Stem Cell Institute, Cambridge, UK

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
NMNimitha R Mathew
Nimitha R Mathew
FBFrancis Baumgartner
Francis Baumgartner
LBLukas Braun
Lukas Braun
DODavid O'Sullivan
David O'Sullivan
STSimone Thomas
Simone Thomas
RZRobert Zeiser
Robert Zeiser

1 February 2018 in Developmental Cell
Verified
Journal Article
Open access
CBCharlotta Böiers
Charlotta Böiers
SRSimon E. Richardson
Simon E. Richardson
ELEmma Laycock
Emma Laycock
AZAlya Zriwil
Alya Zriwil
VTVirginia A. Turati
Virginia A. Turati
TETariq Enver
Tariq Enver
ETV6-RUNX1 is associated with childhood acute B-lymphoblastic leukemia (cALL) functioning as a first-hit mutation that initiates a clinically silent pre-leukemia in utero. Because lineage commitment hierarchies differ between embryo and adult, and the impact of oncogenes is cell-context dependent, we hypothesized that the childhood affiliation of ETV6-RUNX1 cALL reflects its origins in a progenitor unique to embryonic life. We characterize the first emerging B cells in first-trimester human embryos, identifying a developmentally restricted CD19-IL-7R+ progenitor compartment, which transitions from a myeloid to lymphoid program during ontogeny. This developmental series is recapitulated in differentiating human pluripotent stem cells (hPSCs), thereby providing a model for the initiation of cALL. Genome-engineered hPSCs expressing ETV6-RUNX1 from the endogenous ETV6 locus show expansion of the CD19-IL-7R+ compartment, show a partial block in B lineage commitment, and produce proB cells with aberrant myeloid gene expression signatures and potential: features (collectively) consistent with a pre-leukemic state.

1 July 2020 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
TLTheresa E. León
Theresa E. León
TRTanya Rapoz-D'Silva
Tanya Rapoz-D'Silva
CBCosetta Bertoli
Cosetta Bertoli
SRSunniyat Rahman
Sunniyat Rahman
MMMichael Magnussen
Michael Magnussen
MMMarc R. Mansour
Marc R. Mansour
Loss-of-function mutations of EZH2, the enzymatic component of PRC2, have been associated with poor outcome and chemotherapy resistance in T-cell acute lymphoblastic leukemia (T-ALL). Using isogenic T-ALL cells, with and without CRISPR/Cas9–induced EZH2-inactivating mutations, we performed a cell-based synthetic lethal drug screen. EZH2-deficient cells exhibited increased sensitivity to structurally diverse inhibitors of CHK1, an interaction that could be validated genetically. Furthermore, small-molecule inhibition of CHK1 had efficacy in delaying tumor progression in isogenic EZH2-deficient, but not EZH2 wild-type, T-ALL cells in vivo, as well as in a primary cell model of PRC2-mutant ALL. Mechanistically, EZH2 deficiency resulted in a gene-expression signature of immature T-ALL cells, marked transcriptional upregulation of MYCN, increased replication stress, and enhanced dependency on CHK1 for cell survival. Finally, we demonstrate this phenotype is mediated through derepression of a distal PRC2-regulated MYCN enhancer. In conclusion, we highlight a novel and clinically exploitable pathway in high-risk EZH2-mutated T-ALL. Significance: Loss-of-function mutations of PRC2 genes are associated with chemotherapy resistance in T-ALL, yet no specific therapy for this aggressive subtype is currently clinically available. Our work demonstrates that loss of EZH2 activity leads to MYCN-driven replication stress, resulting in increased sensitivity to CHK1 inhibition, a finding with immediate clinical relevance. This article is highlighted in the In This Issue feature, p. 890

24 October 2011 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
SRSimon E. Richardson
Simon E. Richardson
JSJagoda Sudak
Jagoda Sudak
VWVictoria Warbey
Victoria Warbey
ARAlan Ramsay
Alan Ramsay
CMChristopher J. McNamara
Christopher J. McNamara
Accurate staging of classical Hodgkin lymphoma (CHL) directs treatment intensity. Functional imaging can detect marrow/bone involvement making the role of bone marrow biopsy (BMB) unclear. We assessed current UK practice in CHL staging by questionnaire and retrospectively analyzed patients staged at a single center with BMB and 18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). From 34 questionnaire responses 50% used FDG-PET/CT routinely. BMB was employed in 97% with advanced-stage and 30% of patients with limited-stage disease (70% of those not using routine FDG-PET/CT). Ten out of 50 patients were BM+, all of which were identified by FDG-PET/CT (PET+). Conventional BMB changed management in 2% of cases. There were no clinically significant FDG-PET/CT false positives. Conventional routine BMB staging in CHL is extremely insensitive. FDG-PET/CT can rule out marrow/bone involvement in CHL. In the FDG-PET/CT staging era BMB should be targeted to a minority of patients with FDG-PET/CT + bone/marrow uptake and only when management would be altered by the result.

1 March 2019 in Clinical Medicine
Verified
Journal Article
Open access
PDF file
WBWilliam Beedham
William Beedham
GPGeorge Peck
George Peck
SRSimon E Richardson
Simon E Richardson
KTKevin Tsang
Kevin Tsang
MFMichael Fertleman
Michael Fertleman
DSDavid Jh Shipway
David Jh Shipway
Head injury is a common cause for hospital admission and additionally 250,000 UK inpatients fall during hospital admissions annually. Head injury most commonly occurs as a result of falls from standing height in older adults. Older adults are frequently frail and multi-morbid; many have indications for anticoagulation and antiplatelet agents. The haemorrhagic complications of head injury occur in up to 16% of anticoagulated patients sustaining a head injury. These patients suffer adverse outcomes from surgery as a result of medical complications. Although geriatric trauma models are evolving to meet the demand of an ageing trauma population, medical support to trauma services is commonly delivered by general physicians, many of whom lack experience and training in this field. Determining the role of surgery and interrupted anticoagulation requires careful personalised risk assessment. Appreciation of the opposing risks can be challenging; it requires an understanding of the evidence base in both surgery and medicine to rationalise decision making and inform communication. This article aims to provide an overview for the physician with clinical responsibility for patients who have sustained head injury.

3 May 2021 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
RPRachael Pocock
Rachael Pocock
NFNadine Farah
Nadine Farah
SRSimon E. Richardson
Simon E. Richardson
MMMarc R. Mansour
Marc R. Mansour
Summary: T‐cell ALL (T‐ALL) is an aggressive malignancy of T‐cell progenitors. Although survival outcomes in T‐ALL have greatly improved over the past 50 years, relapsed and refractory cases remain extremely challenging to treat and those who cannot tolerate intensive treatment continue to have poor outcomes. Furthermore, T‐ALL has proven a more challenging immunotherapeutic target than B‐ALL. In this review we explore our expanding knowledge of the basic biology of T‐ALL and how this is paving the way for repurposing established treatments and the development of novel therapeutic approaches.